Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by Crossref.
Müller, N
Putz, A
and
Straube, A
1994.
The opiate system inGilles de la Tourettesyndrome: diverse effects of naltrexone treatment.
European Psychiatry,
Vol. 9,
Issue. 1,
p.
39.
Modesto-Lowe, Vania
and
Van Kirk, Jeffrey
2002.
Clinical uses of naltrexone: A review of the evidence..
Experimental and Clinical Psychopharmacology,
Vol. 10,
Issue. 3,
p.
213.
Symons, Frank J.
Thompson, Andrea
and
Rodriguez, Michael C.
2004.
Self‐injurious behavior and the efficacy of naltrexone treatment: A quantitative synthesis.
Mental Retardation and Developmental Disabilities Research Reviews,
Vol. 10,
Issue. 3,
p.
193.
Ward, Frances
Tharian, Priyanka
Roy, Meera
Deb, Shoumitro
and
Unwin, Gemma L.
2013.
Efficacy of beta blockers in the management of problem behaviours in people with intellectual disabilities: A systematic review.
Research in Developmental Disabilities,
Vol. 34,
Issue. 12,
p.
4293.
Deb, Shoumitro
2016.
Handbook of Evidence-Based Practices in Intellectual and Developmental Disabilities.
p.
347.
Sagar-Ouriaghli, Ilyas
Lievesley, Kate
and
Santosh, Paramala J
2018.
Propranolol for treating emotional, behavioural, autonomic dysregulation in children and adolescents with autism spectrum disorders.
Journal of Psychopharmacology,
Vol. 32,
Issue. 6,
p.
641.
Szeleszczuk, Łukasz
and
Frączkowski, Dawid
2022.
Propranolol versus Other Selected Drugs in the Treatment of Various Types of Anxiety or Stress, with Particular Reference to Stage Fright and Post-Traumatic Stress Disorder.
International Journal of Molecular Sciences,
Vol. 23,
Issue. 17,
p.
10099.
Deb, Shoumitro
Roy, Meera
Limbu, Bharati
and
Bertelli, Marco
2022.
Handbook of Autism and Pervasive Developmental Disorder.
p.
1157.
Comments
No Comments have been published for this article.